ClinicalTrials.gg
CompletedNCT04170543Updated Jul 10, 2024Results posted

A Phase 2b Diabetic Kidney Disease Study

A Phase 2 interventional study of MEDI3506 and Placebo in Diabetic Kidney Disease, sponsored by AstraZeneca. Completed at 97 sites in 7 countries. Open to participants aged 18 Years to 101 Years. Per ClinicalTrials.gov, last updated 2024-07-10.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
609
Allocation
Randomized
Ages
18 Years to 101 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 153 studies in Diabetic Nephropathies with a site in United States — 22 open to participants now, 32 under way, 1 of them phase 3. Diabetic Nephropathies · United States.

Enrollment
12th of 120
609 · median 79
Started
2019
with 7 others
Phase 2
54 of 153
5 open now
Registered
103rd of 153
by date
Lead sponsor
4 of 153
AstraZeneca

Among the 153 studies in Diabetic Nephropathies with a site in United States, this one is the 12th largest by enrollment of the 120 interventional ones that give a count, is one of 8 that started in 2019, is one of 54 in phase 2, and was the 103rd registered.

Diabetic Nephropathies

543 studies on the registry are indexed under Diabetic Nephropathies; 110 are open to participants now.

Browse Diabetic Nephropathies studies →

Open to participants now

22 of the 153 studies in Diabetic Nephropathies with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 50 Diabetic Nephropathies studies recruiting now, 23 (46%) set no upper age limit and 16 (32%) stop at 75 or younger; 5 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 101 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Diabetic Nephropathies with a site in United States, or all of them as a file.
02

Study summary

A Phase 2b Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of MEDI3506 in Subjects with Diabetic Kidney Disease

Read the detailed description

This is a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, PK, and immunogenicity of MEDI3506 on top of standard of care, including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and dapagliflozin in adult subjects with diabetic kidney disease, defined as subjects with type 2 diabetes mellitus (T2DM) and an estimated glomerular filtration rate (eGFR) of 25-75 mL/min/1.73 m2 with a UACR in the range of 100-3000 mg/g, who meet all eligibility criteria. Approximately 565 subjects, among multiple countries will be randomized to MEDI3506 dose 1, 2, 3 or dose 4, or placebo during a treatment period of 24 weeks. All subjects will receive Dapagliflozin daily, as administered orally from Day 85 to Day 168. The primary objective is to evaluate the effect of MEDI3506 on albuminuria in subjects with DKD. Secondary objectives include evaluating safety, PK and the incidence of ADA during the treatment period.

03

Conditions studied

  • Diabetic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 101 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Adult men or women ≥ 18 years of age.
  2. Diabetic kidney disease DKD defined as:

    1. diagnosis of T2DM
    2. 25-75 mL/min/1.73 m2
    3. UACR 100-3000 mg albumin/g creatinine
  3. BP ≤ 150/100 mmHg
  4. Stable dose of ACEi or ARB Key Exclusion Criteria
  1. Serum potassium > 5.5 mmol/L 2. Significant hepatic disease 3. > 10.5 % 4. B-type natriuretic peptide level > 200 pg/mL 5. History of heart disease 6. Anticipated dialysis or renal transplantation within 1 year 7. History of underlying condition that predisposes the subject to infections 8. Significant infection (viral, bacterial, or fungal) 9. Amputation due to peripheral artery disease 10. Subjects with a positive diagnostic nucleic acid test for SARS-CoV-2 11. Pregnancy, breastfeeding or intention to become pregnant during the course of the study, 12. Any other medical condition or clinically relevant abnormal findings in physical examination, laboratory results, or (ECG) during screening that, in the opinion of the investigator, may compromise the safety of the subject in the study, reduce the subject's ability to participate in the study, or interfere with evaluation of the product
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
609 participants (actual)

Study arms

  • Experimental
    Group 1

    MEDI3506 Dose 1 plus Dapagliflozin (Day 85 to Day 168).

    Drug: MEDI3506 · Drug: Dapagliflozin

  • Experimental
    Group 2

    MEDI3506 Dose 2 plus Dapagliflozin (Day 85 to Day 168).

    Drug: MEDI3506 · Drug: Dapagliflozin

  • Experimental
    Group 3

    MEDI3506 Dose 3 plus Dapagliflozin (Day 85 to Day 168).

    Drug: MEDI3506 · Drug: Dapagliflozin

  • Experimental
    Group 4

    MEDI3506 Dose 4 plus Dapagliflozin (Day 85 to Day 168).

    Drug: MEDI3506 · Drug: Dapagliflozin

  • Placebo comparator
    Group 5

    Placebo (volume matched) plus Dapagliflozin (Day 85 to Day 168).

    Drug: Placebo · Drug: Dapagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population

    UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

    Time frame: From baseline to Day 169

Secondary outcomes

  1. Percent Change From Baseline to Day 85 (Week 12) in UACR - Per Protocol Population

    UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

    Time frame: From baseline to Day 85

  2. Percent Change From Day 85 (Week 12) to Day 169 (Week 24) in UACR - Per Protocol Population

    UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from Day 85 up to Day 169.

    Time frame: From Day 85 to Day 169

  3. Proportion of Subjects With Reduction in UACR at Day 169 (Week 24) - Per Protocol Population

    UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. Only participants with values at Baseline and Day 169 are included.

    Time frame: Baseline and Day 169

  4. Percent Change From Baseline to Day 169 (Week 24) in UACR - Full Analysis Population

    UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

    Time frame: From baseline to Day 169

  5. Percent Change From Baseline to Day 85 (Week 12) in UACR - Full Analysis Population

    UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

    Time frame: From baseline to Day 85

  6. Proportion of Subjects With Reduction in UACR at Day 169 (Week 24) - Full Analysis Population

    UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. Only participants with values at Baseline and Day 169 are included.

    Time frame: Baseline and Day 169

  7. Immunogenicity of MEDI3506 - PK Analysis Population

    ADA prevalence: number of participants ADA positive (ADA+) at baseline and/or post-baseline. Treatment-induced ADA+: ADA not detected or missing at baseline and at least one post-baseline ADA+. Treatment-boosted ADA+: ADA+ at baseline and baseline titre is boosted by ≥ 4-fold increase at ≥ 1 post-baseline time point. Treatment-emergent ADA+ (TE-ADA + or ADA incidence): Treatment-induced ADA+ OR and Treatment-boosted ADA+.

    Time frame: Day 1 to Day 230

  8. Asymptomatic Participants Tested Positive for COVID-19 During the Study - Safety Analysis Population

    Participants were tested for COVID-19 during the course of the study. Descriptive analysis of asymptomatic participants tested positive for COVID-19 during the study.

    Time frame: Day 1 to Day 230

  9. Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events Among COVID-19 Positive Participants - Safety Analysis Population

    For participants tested positive for COVID-19 during the intervention and follow-up periods, this analysis provides: * the number and proportion of subjects with any treatment-emergent adverse event * the number and proportion of subjects with any treatment-emergent serious adverse event

    Time frame: Day 1 to Day 230

Other outcomes

  1. Plasma Concentration of MEDI3506 - PK Analysis Population

    MEDI3506/Tozorakimab serum concentrations were measured using a validated assay method.

    Time frame: Day 1, Day 29, Day 85 and Day 169

07

Results

Posted Jul 10, 2024
Limitations and caveats
41 randomized participants were excluded from analysis populations in order to avoid heterogeneity in the data (bias, etc.) : * 2 participants did not received any IP * 24 participants were enrolled in phase 2a without having the possibility to be enrolled in phase 2b * 15 participants were randomized in a site with GCP breach (inability to confirm the validity of the data reported) These 41 participants are excluded from Baseline characteristics (558 participants).

Participant flow

Participant flow — Overall Study
MilestonePlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Started1479610195160
Completed99707068120
Not completed4826312740
Withdrew: Death11111
Withdrew: Lost to follow-up33031
Withdrew: Withdrawal by subject136549
Withdrew: Not able to transition to phase 2b801006
Withdrew: Enrolled in site with gcp breach61224
Withdrew: Not treated00002
Withdrew: (crf)1615121717
Withdrew: Due to covid-19 pandemic10100

Outcome measures

PrimaryPercent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

Time frame:
From baseline to Day 169
Reported as:
Least squares mean · Percentage change from baseline
Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population
Percentage change from baselinePlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Percent Change From Baseline to Day 169 (Week 24) in UACR - Per Protocol Population-14.82 (-27.05 to -0.53)-17.25 (-30.69 to -1.19)-31.45 (-42.54 to -18.21)-29.70 (-41.61 to -15.37)-20.96 (-31.32 to -9.04)
Statistical analysis
  • Placebo vs MEDI3506 30 mg · MMRM · p = 0.8338 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -2.85 · 90% CI -22.61 to 21.94MEDI3506 30 mg - Placebo
  • Placebo vs MEDI3506 60 mg · MMRM · p = 0.1169 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -19.52 · 90% CI -35.92 to 1.07MEDI3506 60 mg - Placebo
  • Placebo vs MEDI3506 120 mg · MMRM · p = 0.1774 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -17.47 · 90% CI -34.71 to 4.32MEDI3506 120 mg - Placebo
  • Placebo vs MEDI3506 300 mg · MMRM · p = 0.5379 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -7.22 · 90% CI -24.05 to 13.35
SecondaryPercent Change From Baseline to Day 85 (Week 12) in UACR - Per Protocol Population

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

Time frame:
From baseline to Day 85
Reported as:
Least squares mean · Percentage change from baseline
Percent Change From Baseline to Day 85 (Week 12) in UACR - Per Protocol Population
Percentage change from baselinePlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Percent Change From Baseline to Day 85 (Week 12) in UACR - Per Protocol Population21.60 (7.39 to 37.70)5.77 (-8.00 to 21.60)-9.66 (-21.46 to 3.91)-0.53 (-14.10 to 15.18)2.69 (-8.32 to 15.01)
Statistical analysis
  • Placebo vs MEDI3506 30 mg · MMRM · p = 0.1929 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -13.02 · 90% CI -27.08 to 3.75MEDI3506 30 mg - Placebo
  • Placebo vs MEDI3506 60 mg · MMRM · p = 0.0062 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -25.71 · 90% CI -37.83 to -11.22MEDI3506 60 mg - Placebo
  • Placebo vs MEDI3506 120 mg · MMRM · p = 0.0705 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -18.20 · 90% CI -31.86 to -1.81MEDI3506 120 mg - Placebo
  • Placebo vs MEDI3506 300 mg · MMRM · p = 0.0764 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -15.56 · 90% CI -27.82 to -1.21
SecondaryPercent Change From Day 85 (Week 12) to Day 169 (Week 24) in UACR - Per Protocol Population

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from Day 85 up to Day 169.

Time frame:
From Day 85 to Day 169
Reported as:
Least squares mean · Percentage change from baseline
Percent Change From Day 85 (Week 12) to Day 169 (Week 24) in UACR - Per Protocol Population
Percentage change from baselinePlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Percent Change From Day 85 (Week 12) to Day 169 (Week 24) in UACR - Per Protocol Population-23.26 (-32.77 to -12.39)-17.69 (-29.17 to -4.36)-20.87 (-31.70 to -8.32)-25.87 (-36.49 to -13.47)-19.21 (-28.28 to -9)
Statistical analysis
  • Placebo vs MEDI3506 30 mg · MMRM · p = 0.5474 (Unadjusted two-sided p-value) · Ls mean difference in percent change: 7.25 · 90% CI -11.45 to 29.88MEDI3506 30 mg - Placebo
  • Placebo vs MEDI3506 60 mg · MMRM · p = 0.7920 (Unadjusted two-sided p-value) · Ls mean difference in percent change: 3.11 · 90% CI -14.83 to 24.82MEDI3506 60 mg - Placebo
  • Placebo vs MEDI3506 120 mg · MMRM · p = 0.7711 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -3.40 · 90% CI -20.59 to 17.51MEDI3506 120 mg - Placebo
  • Placebo vs MEDI3506 300 mg · MMRM · p = 0.6163 (Unadjusted two-sided p-value) · Ls mean difference in percent change: 5.27 · 90% CI -11.08 to 24.62
SecondaryProportion of Subjects With Reduction in UACR at Day 169 (Week 24) - Per Protocol Population

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. Only participants with values at Baseline and Day 169 are included.

Time frame:
Baseline and Day 169
Reported as:
Count of participants · Participants
Proportion of Subjects With Reduction in UACR at Day 169 (Week 24) - Per Protocol Population
ParticipantsPlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
UACR reduction > 30%4334283859
UACR reduction > 40%3323232945
UACR reduction > 50%2217192335
SecondaryPercent Change From Baseline to Day 169 (Week 24) in UACR - Full Analysis Population

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

Time frame:
From baseline to Day 169
Reported as:
Least squares mean · Percentage change from baseline
Percent Change From Baseline to Day 169 (Week 24) in UACR - Full Analysis Population
Percentage change from baselinePlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Percent Change From Baseline to Day 169 (Week 24) in UACR - Full Analysis Population-15.82 (-27.33 to -2.49)-13.77 (-27.25 to 2.20)-28.98 (-40.20 to -15.64)-30.94 (-41.93 to -17.86)-21.19 (-31.29 to -9.59)
Statistical analysis
  • Placebo vs MEDI3506 30 mg · MMRM · p = 0.8537 (Unadjusted two-sided p-value) · Ls mean difference in percent change: 2.43 · 90% CI -17.35 to 26.95MEDI3506 30 mg - Placebo
  • Placebo vs MEDI3506 60 mg · MMRM · p = 0.1989 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -15.63 · 90% CI -32.14 to 4.89MEDI3506 60 mg - Placebo
  • Placebo vs MEDI3506 120 mg · MMRM · p = 0.1346 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -17.96 · 90% CI -34.01 to 1.99MEDI3506 120 mg - Placebo
  • Placebo vs MEDI3506 300 mg · MMRM · p = 0.5683 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -6.38 · 90% CI -22.59 to 13.23
SecondaryPercent Change From Baseline to Day 85 (Week 12) in UACR - Full Analysis Population

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed. The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction. The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

Time frame:
From baseline to Day 85
Reported as:
Least squares mean · Percentage change from baseline
Percent Change From Baseline to Day 85 (Week 12) in UACR - Full Analysis Population
Percentage change from baselinePlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Percent Change From Baseline to Day 85 (Week 12) in UACR - Full Analysis Population16.86 (3.59 to 31.83)7.59 (-6.16 to 23.35)-7.23 (-19.29 to 6.63)-5.03 (-17.55 to 9.39)1.35 (-9.52 to 13.53)
Statistical analysis
  • Placebo vs MEDI3506 30 mg · MMRM · p = 0.4226 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -7.93 · 90% CI -22.30 to 9.10MEDI3506 30 mg - Placebo
  • Placebo vs MEDI3506 60 mg · MMRM · p = 0.0287 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -20.61 · 90% CI -33.25 to -5.58MEDI3506 60 mg - Placebo
  • Placebo vs MEDI3506 120 mg · MMRM · p = 0.0498 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -18.73 · 90% CI -31.70 to -3.30MEDI3506 120 mg - Placebo
  • Placebo vs MEDI3506 300 mg · MMRM · p = 0.1236 (Unadjusted two-sided p-value) · Ls mean difference in percent change: -13.27 · 90% CI -25.51 to 0.98
SecondaryProportion of Subjects With Reduction in UACR at Day 169 (Week 24) - Full Analysis Population

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean. Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment. Only participants with values at Baseline and Day 169 are included.

Time frame:
Baseline and Day 169
Reported as:
Count of participants · Participants
Proportion of Subjects With Reduction in UACR at Day 169 (Week 24) - Full Analysis Population
ParticipantsPlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
UACR reduction > 30%4936284162
UACR reduction > 40%3725233248
UACR reduction > 50%2618192638
SecondaryImmunogenicity of MEDI3506 - PK Analysis Population

ADA prevalence: number of participants ADA positive (ADA+) at baseline and/or post-baseline. Treatment-induced ADA+: ADA not detected or missing at baseline and at least one post-baseline ADA+. Treatment-boosted ADA+: ADA+ at baseline and baseline titre is boosted by ≥ 4-fold increase at ≥ 1 post-baseline time point. Treatment-emergent ADA+ (TE-ADA + or ADA incidence): Treatment-induced ADA+ OR and Treatment-boosted ADA+.

Time frame:
Day 1 to Day 230
Reported as:
Count of participants · Participants
Immunogenicity of MEDI3506 - PK Analysis Population
ParticipantsPlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Treatment-induced ADA+16101212
Treatment-boosted ADA+01002
Treatment-emergent ADA+ (Treatment-induced ADA+ or Treatment-boosted ADA+)17101214
Other pre-specifiedPlasma Concentration of MEDI3506 - PK Analysis Population

MEDI3506/Tozorakimab serum concentrations were measured using a validated assay method.

Time frame:
Day 1, Day 29, Day 85 and Day 169
Reported as:
Geometric mean · ng/mL
Plasma Concentration of MEDI3506 - PK Analysis Population
ng/mLPlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Day 10.01063 ± 418.90.005232 ± 38.160.005261 ± 33.330.005111 ± 12.300.005443 ± 79.38
Day 290.01983 ± 533.30.2185 ± 110.30.4454 ± 144.40.7036 ± 119.71.884 ± 64.34
Day 850.02898 ± 711.30.2754 ± 155.60.4701 ± 140.10.9547 ± 103.22.326 ± 80.10
Day 1690.02435 ± 919.40.2495 ± 132.20.4231 ± 188.40.7027 ± 200.12.402 ± 91.04
SecondaryAsymptomatic Participants Tested Positive for COVID-19 During the Study - Safety Analysis Population

Participants were tested for COVID-19 during the course of the study. Descriptive analysis of asymptomatic participants tested positive for COVID-19 during the study.

Time frame:
Day 1 to Day 230
Reported as:
Count of participants · Participants
Asymptomatic Participants Tested Positive for COVID-19 During the Study - Safety Analysis Population
ParticipantsPlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Asymptomatic Participants Tested Positive for COVID-19 During the Study - Safety Analysis Population7954505370
SecondaryTreatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events Among COVID-19 Positive Participants - Safety Analysis Population

For participants tested positive for COVID-19 during the intervention and follow-up periods, this analysis provides: * the number and proportion of subjects with any treatment-emergent adverse event * the number and proportion of subjects with any treatment-emergent serious adverse event

Time frame:
Day 1 to Day 230
Reported as:
Count of participants · Participants
Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events Among COVID-19 Positive Participants - Safety Analysis Population
ParticipantsPlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Any adverse event4735233040
Any serious adverse event119163

Adverse events

Collected over Day 1 to Day 230. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo1/133 (0.8%)15/133 (11.3%)62/133 (46.6%)
MEDI3506 30 mg1/95 (1.1%)14/95 (14.7%)55/95 (57.9%)
MEDI3506 60 mg1/89 (1.1%)5/89 (5.6%)39/89 (43.8%)
MEDI3506 120 mg1/93 (1.1%)12/93 (12.9%)48/93 (51.6%)
MEDI3506 300 mg1/148 (0.7%)11/148 (7.4%)74/148 (50%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventPlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
Atrial fibrillationCardiac disorders0/1330/950/892/930/148
HyperkalaemiaMetabolism and nutrition disorders0/1332/950/890/930/148
Acute kidney injuryRenal and urinary disorders2/1331/950/891/931/148
Covid-19Infections and infestations1/1330/951/890/931/148
Septic shockInfections and infestations0/1330/951/891/930/148
Cardio-respiratory arrestCardiac disorders0/1330/951/890/930/148
HypervolaemiaMetabolism and nutrition disorders0/1330/951/890/930/148
HypovolaemiaMetabolism and nutrition disorders0/1330/951/890/930/148
Intervertebral disc degenerationMusculoskeletal and connective tissue disorders0/1330/951/890/930/148
FaecalomaGastrointestinal disorders0/1330/951/890/930/148
Most frequent other events
Showing 10 of 252
Most frequent other events
EventPlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mg
HypoglycaemiaMetabolism and nutrition disorders0/1338/950/892/932/148
HypertensionVascular disorders3/1336/951/897/937/148
HyperkalaemiaMetabolism and nutrition disorders5/1334/955/893/939/148
Back painMusculoskeletal and connective tissue disorders4/1335/952/893/931/148
Covid-19Infections and infestations6/1333/953/894/935/148
Urinary tract infectionInfections and infestations5/1333/954/890/933/148
DiarrhoeaGastrointestinal disorders2/1331/954/893/934/148
ArthralgiaMusculoskeletal and connective tissue disorders2/1334/950/890/934/148
Oedema peripheralGeneral disorders4/1334/951/892/936/148
PyrexiaGeneral disorders2/1334/950/891/932/148

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mgTotal
Mean66.7 ± 9.767.1 ± 9.867.2 ± 10.166.6 ± 9.765.9 ± 10.166.6 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mgTotal
Sex — Female4633232443169
Sex — Male87626669105389
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mgTotal
Ethnicity — Hispanic or Latino6162315381288
Ethnicity — Not Hispanic or Latino7233584067270
Ethnicity — Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mgTotal
Race — American Indian or Alaska Native2501412
Race — Asian2915241729114
Race — Native Hawaiian or Other Pacific Islander113128
Race — Black or African American166941348
Race — White8168536696364
Race — More than one race100001
Race — Unknown or Not Reported3004411
Region of Enrollment
Region of Enrollment(Participants)PlaceboMEDI3506 30 mgMEDI3506 60 mgMEDI3506 120 mgMEDI3506 300 mgTotal
Argentina2028122825113
Canada4272621
Chile1312291753
Japan201115111875
Korea, Republic of; South Korea4323315
Peru030047
United States7236514075274
08

Study locations

97 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Mesa, Arizona 85210, United States
  • Research Site
    Alhambra, California 91801, United States
  • Research Site
    Glendale, California 91204, United States
  • Research Site
    Granada Hills, California 91344, United States
  • Research Site
    Huntington Park, California 90255, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Sacramento, California 95821, United States
  • Research Site
    San Diego, California 92123, United States
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    Vacaville, California 95687, United States
  • Research Site
    Fleming Island, Florida 32003, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Jacksonville, Florida 32204, United States
  • Research Site
    Miami, Florida 33015, United States
  • Research Site
    Atlanta, Georgia 30338, United States
  • Research Site
    Honolulu, Hawaii 96814, United States
  • Research Site
    Chicago, Illinois 60607, United States
  • Research Site
    Chicago, Illinois 60643, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Manhattan, Kansas 66502, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Henderson, Nevada 89014, United States
  • Research Site
    Las Vegas, Nevada 89129, United States
  • Research Site
    Berlin, New Jersey 08009, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Greensboro, North Carolina 27408, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Morehead City, North Carolina 28557, United States
  • Research Site
    Maumee, Ohio 43537, United States
  • Research Site
    Oklahoma City, Oklahoma 73116, United States
  • Research Site
    Bethlehem, Pennsylvania 18017, United States
  • Research Site
    East Providence, Rhode Island 02915, United States
  • Research Site
    Columbia, South Carolina 29203, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Cypress, Texas 77429, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77079, United States
  • Research Site
    Katy, Texas 77450, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    San Antonio, Texas 78251, United States
  • Research Site
    Saint George, Utah 84790, United States
  • Research Site
    Burke, Virginia 22015, United States
  • Research Site
    Tacoma, Washington 98405, United States
  • Research Site
    Morgantown, West Virginia 26506, United States
  • Research Site
    Buenos Aires, 1425DES, Argentina
  • Research Site
    Buenos Aires, C1056ABJ, Argentina
  • Research Site
    Buenos Aires, C1429BWN, Argentina
  • Research Site
    Caba, C1120AAC, Argentina
  • Research Site
    Caba, C1128AAF, Argentina
  • Research Site
    Caba, C1425AGC, Argentina
  • Research Site
    Cordoba, X5000AAW, Argentina
  • Research Site
    Corrientes, W3400AMZ, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Pergamino, B2700LDK, Argentina
  • Research Site
    Ramos Mejía, B1704ETD, Argentina
  • Research Site
    Rosario, S2000DNM, Argentina
  • Research Site
    San Luis, D5700CTA, Argentina
  • Research Site
    San Nicolás, B2900DMH, Argentina
  • Research Site
    San Vicente, 5006, Argentina
  • Research Site
    Calgary, Alberta T2H 2G4, Canada
  • Research Site
    Red Deer, Alberta T4N 6V7, Canada
  • Research Site
    Brampton, Ontario L6S 0S9, Canada
  • Research Site
    Brampton, Ontario L6T 0G1, Canada
  • Research Site
    Concord, Ontario L4K 4M2, Canada
  • Research Site
    Etobicoke, Ontario M9R 4E1, Canada
  • Research Site
    Toronto, Ontario M4G 3E8, Canada
  • Research Site
    Concepción, Chile
  • Research Site
    Nunoa, 8520398, Chile
  • Research Site
    Santiago, 7500021, Chile
  • Research Site
    Santiago, 7500710, Chile
  • Research Site
    Santiago, 8320000, Chile
  • Research Site
    Santiago, Chile
  • Research Site
    Victoria, Chile
  • Research Site
    Chuo-ku, 103-0027, Japan
  • Research Site
    Fukuoka-shi, 815-8555, Japan
  • Research Site
    Ise-shi, 516-8512, Japan
  • Research Site
    Kisarazu-shi, 292-8535, Japan
  • Research Site
    Koshigaya-shi, 343-8577, Japan
  • Research Site
    Nagano-shi, 388-8004, Japan
  • Research Site
    Nagoya, 451-8511, Japan
  • Research Site
    Nishinomiya-Shi, 662-0918, Japan
  • Research Site
    Osaka-shi, 530-0001, Japan
  • Research Site
    Osaka-shi, 558-8558, Japan
  • Research Site
    Sayama-Shi, Japan
  • Research Site
    Gangnam-Gu, 6273, Korea, Republic of
  • Research Site
    Goyang-si, 10444, Korea, Republic of
  • Research Site
    Jongno-gu, 110-746, Korea, Republic of
  • Research Site
    Seongbuk-Gu, 02841, Korea, Republic of
  • Research Site
    Seoul, 06351, Korea, Republic of
  • Research Site
    Suwon, 16499, Korea, Republic of
  • Research Site
    Wonju-si, 26426, Korea, Republic of
  • Research Site
    Piura, Peru
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access.For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in May 2023, 41 months.

Results were first posted in Jul 2024, 1 year 1 month after primary completion.

Of 32 industry-sponsored phase 2 interventional studies under Diabetic Nephropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's 41 months is above that.

Counting every sponsor, half of 52 studies reached it within 21 months; a quarter within 13 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2019
First posted
Nov 20, 2019
StartActual
Nov 18, 2019
Primary completionActual
May 16, 2023
CompletionActual
May 16, 2023
Results first posted
Jul 10, 2024
Last update
Jul 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04170543
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 20, 2019
Start date
Nov 18, 2019
Primary completion
May 16, 2023
Completion
May 16, 2023
Results posted
Jul 10, 2024
Last update
Jul 10, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tozorakimab

Start the discussion